伊诺维奥制药与康方生物宣布，双方已就一项针对胶质母细胞瘤（GBM）的新型联合疗法达成临床合作协议。此次合作旨在加速该创新疗法的研发进程，为胶质母细胞瘤患者探索新的治疗选择。
胶质母细胞瘤是一种侵袭性强、预后较差的脑部恶性肿瘤，目前临床治疗选择有限，存在巨大的未满足医疗需求。两家公司计划通过联合各自的优势研发平台与技术，推动该联合疗法的临床开发，以期改善患者的生存预后。
此次合作将结合伊诺维奥制药在免疫疗法领域的专长与康方生物在肿瘤创新药物开发方面的经验。双方期待通过资源整合与协同效应，加速这一重要治疗方案的开发步伐，为全球胶质母细胞瘤患者带来新的希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.